ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Todays Updates

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Todays Updates

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

Carmela Tartaglia, MD, FRCPC, discusses the challenges of diagnosing frontotemporal dementia, the evolving role of biomarkers, and emerging approaches to disease modification.

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 9, 2026.

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Phase 3 ABTECT data show ~51% clinical remission and ≥40% endoscopic remission with obefazimod through week 44.

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Obefazimod could work as first, second, or third line therapy in ulcerative colitis ahead of a planned FDA submission this year.

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Arjan Bredenoord, MD, details how tezepelumab's selective TSLP inhibition sustained EoE remission through week 52 of the CROSSING trial.

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

ALOFT-IPF: Admilparant 60 mg Meets Primary FVC End Point

Latest News

Residual Asthma Exacerbations on Biologics Vary by Mechanism

Dupilumab's IL-4/IL-13 Blockade Drives Efficacy Edge in EVEREST Guy Brusselle, MD, PhD

Verekitug Reduces Asthma Exacerbations Up to 87%, With Michael Wechsler, MD Michael Wechsler, MD, MSc

8 Pulmonology Headlines You Missed in Q3 2026

8 Pulmonology Headlines You Missed in September 2026

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Todays Updates

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Todays Updates

Frontotemporal Dementia Diagnosis, Head Impacts, and Emerging Treatment Approaches Louie Pasculli, Carme Tartaglia, MD

NeurologyLive® Friday 5 — October 9, 2026 Isabella Ciccone, MPH

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

ABTECT Maintenance Data Show Durable Remission in UC, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Where Could Obefazimod Fit in UC Treatment, With Remo Panaccione, MD Remo Panaccione, MD, FRCPC

Tezepelumab's TSLP Blockade May Address Refractory EoE Gap Arjan Bredenoord, MD

Long-Term Risankizumab Data Show Durable Crohn’s, Fistula Outcomes

Latest News

News All Time

Zumilokibart Rapidly Suppresses FeNO in Phase 1b Asthma Data: Mario Castro, MD Mario Castro, MD, MPH

BEAM-302 Base Editing Sustains Protective AAT, With John Hurst, MBBS, PhD John Hurst, MBBS, PhD

Dupilumab Scores on Win-Ratio Analysis in Pediatric Asthma: Sharon Dell, MD Sharon Dell, MD

PDGF Pathway in PAH: Setbacks and Promise, With Olivier Sitbon, MD, PhD Olivier Sitbon, MD, PhD

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD Njira Lugogo, MD

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD Njira Lugogo, MD

Verekitug's TSLP Mechanism and VALIANT Trial Results, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Tozorakimab Cuts COPD Exacerbations Across Eosinophil Levels: Frank Sciurba, MD Frank C. Sciurba, MD

Semaglutide Cuts Asthma Attacks by up to 40% in Real-World Study Victoria Johnson

FIBRONEER-ON: Nerandomilast's Durable IPF, PPF Safety, With Wim Wuyts, MD, PhD Wim Wuyts, MD, PhD

Dupilumab Cuts COPD Exacerbations Across Seasons, Smoking Status: Surya Bhatt, MD Surya P. Bhatt, MD

Oral STAT6 Degraders Fill Niche in Asthma Care, With Michael Wechsler, MD Michael Wechsler, MD, MSc

Rademikibart Improves FEV1 in Phase 2 Asthma Exacerbation Trial Victoria Johnson

STAT6 Degradation: A Novel Oral Target for Asthma? Victoria Johnson

FDA Grants Priority Review for Insmed's ARIKAYCE sNDA for MAC Lung Disease

ERS Congress 2026: 6 Late-Breaking Trials to Know Victoria Johnson

Recommended News For You

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace

NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.

Should the UK introduce targeted prostate cancer screening? The case for and against

Ranking of the Best US Hospitals for Psychiatric Care.

Response Duration After Stopping Enfortumab Vedotin in Bladder Cancer

Reversing the toxic relationship with high doses of chemotherapy in oncology.

Laser Therapy Shows Promise for Brain Tumors

Recommended Articles For You

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends

Case Study: The Role of JAK Inhibitors in Myeloproliferative Disorders

Understanding Fibrosarcoma: What You Need to Know

The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.